Bristol Myers Squibb’s Breyanzi receives EC approval to treat LBCL

Bristol Myers Squibb has received approval from the European Commission (EC) for its cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients.

The therapy is indicated to treat diffuse LBCL (DLBCL) primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL) and follicular lymphoma grade 3B (FL3B) in adult patients whose disease relapsed within 12 months of completion of first-line chemoimmunotherapy, or who were refractory to it.

It is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain that improves CAR T cells’ expansion and persistence.

The regulatory approval covers all EU member states.

Bristol Myers Squibb senior vice-president and cell therapy development head Anne Kerber stated: “With Breyanzi, people in Europe living with relapsed or refractory DLBCL now have a differentiated CAR T cell therapy option earlier in the treatment paradigm that provides long-term clinical benefit.

“This marks the approval of our third indication in Europe for our CAR T cell therapy portfolio, underscoring our continued drive to deliver the promise of cell therapy with curative potential for more patients.”

The EC’s approval is based on the data obtained from the pivotal Phase III TRANSFORM trial.

The multicentre, randomised, global, pivotal trial assessed Breyanzi in relapsed or refractory LBCL patients against the existing standard of care.

Breyanzi showed statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS), as well as the important secondary endpoints of progression-free survival (PFS) and complete responses (CR) compared to standard therapy.

In December 2022, Japan granted approval for Bristol-Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel; liso-cel) as second-line therapy to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) patients.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By Cytiva Thematic

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy